Nature, Published online: 01 October 2025; doi:10.1038/d41586-025-03163-9

After an initial treatment response, most ovarian cancers recur because of drug-resistant cell populations. Blood-based tracking, used to monitor clonal evolution in 18 patients, shows that drug-resistant clones are already present at diagnosis, expand during therapy and contain distinctive genomic alterations that have potential therapeutic relevance.

From Nature via this RSS feed